Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60-Reference-Cited by-同舟云学术

Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60

Published:2021-10-13 Issue:2 Volume:57 Page:160-166
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Pollyea Daniel A.,Winters Amanda,McMahon Christine,Schwartz Marc,Jordan Craig T.^ORCID,Rabinovitch Rachel,Abbott Diana,Smith Clayton A.,Gutman Jonathan A.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-021-01476-7.pdf

Reference40 articles.

1. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–5. https://doi.org/10.1182/blood-2005-09-3724. e-pub ahead of print 2006/02/04.

2. Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR. Outcome of older patients with acute myeloid leukemia: An analysis of SEER data over 3 decades. Cancer. 2013;119:2720–7. https://doi.org/10.1002/cncr.28129. e-pub ahead of print 2013/05/02.

3. Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235–48. https://doi.org/10.1056/NEJMoa0901409. e-pub ahead of print 2009/09/25.

4. Vasu S, Kohlschmidt J, Mrozek K, Eisfeld AK, Nicolet D, Sterling LJ, et al. Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv. 2018;2:1645–50. https://doi.org/10.1182/bloodadvances.2017015222. e-pub ahead of print 2018/07/12.

5. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Disco. 2014;4:362–75. https://doi.org/10.1158/2159-8290.CD-13-0609. e-pub ahead of print 2013/12/19.

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global, regional, and national burden of acute myeloid leukemia, 1990–2021: a systematic analysis for the global burden of disease study 2021;Biomarker Research;2024-09-11

2. Approaches to anticancer therapy based on modulation of DNA methylation;Siberian journal of oncology;2024-09-09

3. Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia;Leukemia & Lymphoma;2024-09-04

4. Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study;Annals of Hematology;2024-08-29

5. Improved Outcome of Allogeneic Transplantation in Older Patients Treated for Myeloid Malignancies Using Post-Transplantation Cyclophosphamide and Reduced Duration of Immune Suppression;Transplantation and Cellular Therapy;2024-08